GAITHERSBURG, Md., Sept. 28, 2016 /PRNewswire/ -- GenVec, Inc.
(NASDAQ: GNVC), a clinical-stage gene delivery company, announced
that Douglas E. Brough, Ph.D., the
company's chief scientific officer, will present "Exploring
the AdenoVerse™ Platform for New Advanced Cell and Gene
Therapies", a brief review of GenVec's technology
platform, at the 2016 Cell & Gene Meeting on the Mesa
(CGMOM). This presentation will highlight new data that
demonstrate the utility of select AdenoVerse vectors for efficient
gene delivery to immune system cells, including T cells. GenVec
believes that these vectors can be applied for therapeutic
approaches focusing on genetically modified human primary T cells.
GenVec has extensive expertise translating innovative product
concepts from the laboratory to the clinic. The company's
proprietary vectors are particularly well suited for the delivery
of large therapeutic gene payloads, including gene editing
technologies, for a wide a variety of treatment
strategies.
Dr. Brough's presentation is scheduled for Wednesday, October 5, beginning at 11 a.m. PDT/2:00 p.m.
EDT. A live video webcast of all company presentations at
the CGMOM will be available at:
www.meetingonthemesa.com/webcast during the proceedings; and the
slides from Dr. Brough's presentation will be posted for review at
www.genvec.com in the Media section, presentations
collection. GenVec will post a video replay of Dr. Brough's
talk on the company website at the same location when the video
clip becomes available after the meeting
concludes.
About GenVec
GenVec is a clinical-stage gene delivery company focused on
developing a pipeline of cutting-edge therapeutics and vaccines
using its proprietary AdenoVerse platform. The company is a pioneer
in the design, testing and manufacture of adenoviral-based product
candidates that can deliver on the promise of gene-based medicine.
GenVec's lead product candidate, CGF166, is licensed to Novartis
and is currently in a Phase 1/2 clinical study for the treatment of
hearing loss and balance disorders. In addition to its internal and
partnered pipeline, the company is also focused on opportunities to
license its proprietary technology platform, including vectors and
production cell lines, for the development and manufacture of
therapeutics and vaccines to the biopharmaceutical industry.
Additional information about GenVec is available at www.genvec.com
and in the company's various filings with the Securities and
Exchange Commission.
Statements herein relating to future business performance,
conditions or strategies and other financial and business matters,
including with respect to expansion of the reach of GenVec's
technology platform, are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act.
GenVec cautions that these forward-looking statements are subject
to numerous assumptions, risks and uncertainties, which change over
time. Factors that may cause actual results to differ
materially from the results discussed in the forward-looking
statements or historical experience include risks and
uncertainties, including the failure by GenVec to secure and
maintain relationships with collaborators; risks relating to
clinical trials; risks relating to the commercialization, if any,
of GenVec's proposed product candidates (such as marketing,
regulatory, patent, product liability, supply, competition and
other risks); dependence on the efforts of third parties;
dependence on intellectual property; and risks that we may lack the
financial resources and access to capital to fund our
operations. Further information on the factors and risks that
could affect GenVec's business, financial conditions and results of
operations are contained in GenVec's filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
www.sec.gov. The forward-looking statements speak only
as of the date of this presentation, and GenVec assumes no duty to
update forward-looking statements.
Contact:
GenVec,
Inc.
Rena
Cohen
(240)
632-5501
rcohen@genvec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genvec-to-present-at-2016-cell--gene-meeting-on-the-mesa-300335436.html
SOURCE GenVec, Inc.